Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone in Previously Untreated Primary ITP
NCT07700238Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of romiplostim in primary immune thrombocytopenia (ITP) (2 arms), sponsored by Amgen. Primary endpoint: Durable Platelet Response at 8 weeks. Started Aug 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07700238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07700238.